S&P 500   3,741.00 (-1.32%)
DOW   30,004.06 (-1.03%)
QQQ   277.02 (-1.81%)
AAPL   144.19 (-1.31%)
MSFT   245.36 (-1.41%)
META   135.62 (-3.32%)
GOOGL   99.30 (-2.30%)
AMZN   118.72 (-1.96%)
TSLA   233.63 (-6.34%)
NVDA   127.88 (-2.88%)
NIO   15.76 (-5.80%)
BABA   83.65 (-0.55%)
AMD   65.91 (-2.93%)
T   15.85 (-1.49%)
MU   53.48 (-0.89%)
CGC   2.98 (-5.10%)
F   12.28 (-0.65%)
GE   66.84 (-1.04%)
DIS   99.26 (-2.15%)
AMC   7.16 (-8.56%)
PYPL   91.35 (-1.55%)
PFE   43.85 (-1.37%)
NFLX   229.20 (-4.79%)
S&P 500   3,741.00 (-1.32%)
DOW   30,004.06 (-1.03%)
QQQ   277.02 (-1.81%)
AAPL   144.19 (-1.31%)
MSFT   245.36 (-1.41%)
META   135.62 (-3.32%)
GOOGL   99.30 (-2.30%)
AMZN   118.72 (-1.96%)
TSLA   233.63 (-6.34%)
NVDA   127.88 (-2.88%)
NIO   15.76 (-5.80%)
BABA   83.65 (-0.55%)
AMD   65.91 (-2.93%)
T   15.85 (-1.49%)
MU   53.48 (-0.89%)
CGC   2.98 (-5.10%)
F   12.28 (-0.65%)
GE   66.84 (-1.04%)
DIS   99.26 (-2.15%)
AMC   7.16 (-8.56%)
PYPL   91.35 (-1.55%)
PFE   43.85 (-1.37%)
NFLX   229.20 (-4.79%)
S&P 500   3,741.00 (-1.32%)
DOW   30,004.06 (-1.03%)
QQQ   277.02 (-1.81%)
AAPL   144.19 (-1.31%)
MSFT   245.36 (-1.41%)
META   135.62 (-3.32%)
GOOGL   99.30 (-2.30%)
AMZN   118.72 (-1.96%)
TSLA   233.63 (-6.34%)
NVDA   127.88 (-2.88%)
NIO   15.76 (-5.80%)
BABA   83.65 (-0.55%)
AMD   65.91 (-2.93%)
T   15.85 (-1.49%)
MU   53.48 (-0.89%)
CGC   2.98 (-5.10%)
F   12.28 (-0.65%)
GE   66.84 (-1.04%)
DIS   99.26 (-2.15%)
AMC   7.16 (-8.56%)
PYPL   91.35 (-1.55%)
PFE   43.85 (-1.37%)
NFLX   229.20 (-4.79%)
S&P 500   3,741.00 (-1.32%)
DOW   30,004.06 (-1.03%)
QQQ   277.02 (-1.81%)
AAPL   144.19 (-1.31%)
MSFT   245.36 (-1.41%)
META   135.62 (-3.32%)
GOOGL   99.30 (-2.30%)
AMZN   118.72 (-1.96%)
TSLA   233.63 (-6.34%)
NVDA   127.88 (-2.88%)
NIO   15.76 (-5.80%)
BABA   83.65 (-0.55%)
AMD   65.91 (-2.93%)
T   15.85 (-1.49%)
MU   53.48 (-0.89%)
CGC   2.98 (-5.10%)
F   12.28 (-0.65%)
GE   66.84 (-1.04%)
DIS   99.26 (-2.15%)
AMC   7.16 (-8.56%)
PYPL   91.35 (-1.55%)
PFE   43.85 (-1.37%)
NFLX   229.20 (-4.79%)

Invitae - NVTA Stock Forecast, Price & News

$2.69
-0.17 (-5.94%)
(As of 10/5/2022 11:34 AM ET)
Add
Compare
Today's Range
$2.60
$2.76
50-Day Range
$1.90
$8.63
52-Week Range
$1.83
$29.15
Volume
153,174 shs
Average Volume
10.74 million shs
Market Capitalization
$632.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.56

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
374.2% Upside
$13.56 Price Target
Short Interest
Healthy
16.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
-0.18mentions of Invitae in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$152,009 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.63) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

122nd out of 1,087 stocks

Medical Laboratories Industry

4th out of 30 stocks

NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Invitae (NYSE: NVTA) Share Price and News
Invitae (NYSE:NVTA) Raised to Sell at StockNews.com
Why Invitae Stock Is Jumping Today
Cathie Wood Has Been Buying These Two Stocks Relentlessly
Invitae to Present at Upcoming Investor Conference
Is It Too Late to Buy Invitae Stock? - Nasdaq
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
8/09/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.56
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+404.2%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
12 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-620.70%
Pretax Margin
-631.07%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$13.16 per share

Miscellaneous

Free Float
232,678,000
Market Cap
$632.88 million
Optionable
Optionable
Beta
1.61

Key Executives

  • Mr. Kenneth D. Knight (Age 61)
    Pres, CEO & Director
    Comp: $1M
  • Ms. Yafei Wen (Age 49)
    Chief Financial Officer
    Comp: $422.73k
  • Mr. Thomas R. BridaMr. Thomas R. Brida (Age 51)
    Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $425k
  • Dr. Robert L. Nussbaum M.D.Dr. Robert L. Nussbaum M.D. (Age 72)
    Chief Medical Officer
    Comp: $391.35k
  • Ms. Shelly D. GuyerMs. Shelly D. Guyer (Age 62)
    Chief Sustainability Officer
    Comp: $430.44k
  • Mr. Robert F. Werner (Age 49)
    Chief Accounting Officer & Principal Accounting Officer
  • Mr. Jackson J. Finks C.F.A.
    CFA, Director of Investor Relations & Strategic Fin.
  • Mr. Lee Bendekgey J.D. (Age 64)
    Chief Policy Officer
  • Glenn Medalle
    Head of Talent
  • Ms. Desarie French
    Chief Talent Officer













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2022?

12 Wall Street research analysts have issued 12 month price targets for Invitae's stock. Their NVTA share price forecasts range from $6.00 to $25.00. On average, they expect the company's stock price to reach $13.56 in the next twelve months. This suggests a possible upside of 374.2% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2022?

Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA shares have decreased by 81.3% and is now trading at $2.86.
View the best growth stocks for 2022 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its earnings results on Tuesday, August, 9th. The medical research company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.06. The medical research company had revenue of $136.62 million for the quarter, compared to analyst estimates of $137.47 million. Invitae had a negative net margin of 620.70% and a negative trailing twelve-month return on equity of 29.91%.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its second quarter 2022 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $136.00 million-$136.00 million, compared to the consensus revenue estimate of $142.74 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a number of institutional and retail investors. Top institutional investors include AdvisorNet Financial Inc (0.00%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.86.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $672.87 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.48) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.